Home »
NYT
» In a trial, Pfizer-BioNTech’s low-dose shot did not provoke an adequate immune response in 2- to 5-year-olds.
In a trial, Pfizer-BioNTech’s low-dose shot did not provoke an adequate immune response in 2- to 5-year-olds.
By BY APOORVA MANDAVILLI AND REBECCA ROBBINS from NYT World https://ift.tt/3sf8pnX
No comments:
Post a Comment